RxDoctor Payments Data

Rebecca O'Shields, APRN

Family · Mc Crory, ARNPI 1255887550

Payments from drug & device makers

$324in general payments, 2019–2025

Across 19 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$109
  • Abbott$70
  • Lilly USA, LLC$32
  • Phathom Pharmaceuticals, Inc.$24
  • Hologic Sales And Service, LLC$22
  • AstraZeneca$19
  • plus $49 from 3 others

What the payments were for

  • Food & beverage$324100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$324 in reported general payments places this provider in the 45th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$4,586
Medicare patients
118
Services billed
271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol99$93,009
EliquisApixaban103$82,257
MounjaroTirzepatide72$76,422
OzempicSemaglutide73$75,669
Tresiba Flextouch U-200Insulin Degludec32$21,738
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$19,468
JardianceEmpagliflozin11$15,534
LinzessLinaclotide15$13,086
TradjentaLinagliptin16$12,940
Combivent RespimatIpratropium/Albuterol Sulfate12$5,893
SymbicortBudesonide/Formoterol Fumarate15$3,804
Gabapentin124$2,541
Ventolin HfaAlbuterol Sulfate44$2,441
Levemir FlexpenInsulin Detemir15$2,213
Temazepam31$1,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$19$96,813114 claims
Lilly USA, LLCMounjaro$32$76,42272 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$109$34,36739 claims
AbbVieLinzess$17$13,08615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,103 family providers in Arkansas.

Other family in Mc Crory

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →